Rivermark Medical, a private urology-focused device company, drew investor attention this week after securing $20 million in Series D funding to advance its FloStent System for benign prostatic hyperplasia (BPH). The round was led by Andera Partners, with participation from existing investors and a new strategic backer, and is intended to fund the pivotal RAPID III clinical trial and U.S. launch preparations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
FloStent is designed as a non-surgical, fully reversible, first-line device therapy for men with lower urinary tract symptoms due to BPH, placed during routine cystoscopy using standard urology tools. The device can be retrieved or adjusted after placement, preserving future treatment options and potentially differentiating Rivermark in the BPH treatment pathway.
The financing follows positive multicenter RAPID II data, which showed rapid recovery and sustained symptom relief out to 24 months, strengthening the clinical rationale as Rivermark moves toward a pivotal study. CEO and co-founder Dr. Adam Kadlec said the new capital extends the company’s runway through key milestones including pivotal trial execution, regulatory filing, and initial commercialization planning in the U.S.
As part of the transaction, Andera partner Aneta Sottil joined Rivermark’s board, adding investor oversight during the regulatory and commercialization phase. The expanded syndicate now includes American Century Investments, Clarevia Ventures, Time BioVentures, View Ventures, Cadence Healthcare Ventures, Anduril Investors, and an undisclosed strategic partner, providing additional capital depth and potential channel support.
In parallel with the financing news, Rivermark highlighted its planned participation at the American Urological Association’s AUA 2026 meeting in Washington, D.C., using LinkedIn to invite urology professionals to schedule meetings via an online booking link. The company emphasized targeted outreach to key clinical stakeholders as part of its long-term strategy to build awareness and gather feedback on FloStent.
Rivermark reiterated that FloStent remains an investigational device under U.S. federal law, limited to investigational use while pivotal data are collected. Taken together, the fresh capital, strengthened board, and proactive specialist engagement suggest the company is building both clinical and commercial foundations, positioning it for a potentially significant inflection once regulatory and trial outcomes become clear.